BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform spanning drug discovery through to investigational new drug submission.
The collaboration brings together BioDuro’s discovery chemistry, biology, drug metabolism and pharmacokinetics, pharmacology, and API and drug product development and manufacturing with CTI Biotechnology’s GLP toxicology and bioanalytical services.
The companies said the combined offering will provide global biotech and pharmaceutical clients with more efficient and flexible development options.
Under the agreement, BioDuro will support discovery and development activities and provide IND filing support across global markets, while CTI Biotechnology will deliver GLP toxicology studies and bioanalytical capabilities to help prepare programmes for successful IND submission.
By coordinating project execution and integrating their complementary expertise, the partners aim to streamline workflows, reduce communication complexity and accelerate the advancement of innovative therapies.
Armin Spura, CEO of BioDuro, said: “Successful IND submission depends on strong execution across every critical step of early development, and GLP toxicology is one of the most important milestones in that journey. By combining BioDuro’s integrated discovery and development capabilities with CTI’s proven expertise in GLP toxicology and bioanalytical services, we are strengthening our ability to help clients move innovative programs forward with greater speed, confidence, and efficiency.”
Tony Liu, General Manager of CTI Biotechnology, explained: “Our strategic collaboration with BioDuro will further enhance our combined service capabilities in preclinical development and provide clients worldwide with a more complete and efficient integrated solution.”
He said: “We look forward to working closely together to help accelerate our clients’ R&D programs and bring more innovative therapies to patients around the world.”
